2型糖尿病患者合并肝功能异常的研究进展

潘秀珍; 戚筠; 杨杨

doi:10.3969/j.issn.1001-5256.2020.10.046

2型糖尿病患者合并肝功能异常的研究进展

DOI: 10.3969/j.issn.1001-5256.2020.10.046

1. 武汉科技大学临床学院
2. 武汉科技大学附属天佑医院内分泌科

详细信息

中图分类号: R587.2;R575
计量
- 文章访问数: 929
- HTML全文浏览量: 28
- PDF下载量: 102
- 被引次数: 0
出版历程
- 收稿日期: 2020-03-29
- 出版日期: 2020-10-20

Research advances in liver dysfunction in patients with type 2 diabetes

Clinical College,Wuhan University of Science and Technology
Department of Endocrinology,Tianyou Hospital Affiliated to Wuhan University of Science and Technology

摘要

摘要: 糖尿病是一种以慢性高血糖为特征的内分泌代谢性疾病。2型糖尿病及其并发症的危害更为明显。2型糖尿病不仅是最常见的糖尿病类型,也是并发症最多的糖尿病。研究发现,2型糖尿病除易并发心脑血管疾病、眼病、肾脏疾病以及神经系统疾病外,还常伴有高血压、血脂异常以及肝功能异常等疾病,对机体造成严重损害。就2型糖尿病与肝功能异常的关系及其相关的疾病学特点进行综述,以期加深对2型糖尿病患者合并肝功能异常的了解,为其临床诊治提供参考。
- 糖尿病,2型 /
- 糖尿病并发症 /
- 非酒精性脂肪性肝病 /
- 肝硬化
Abstract: Diabetes mellitus is an endocrine and metabolic disease characterized by chronic hyperglycemia. Type 2 diabetes is not only the most common type of diabetes,but also the one with the most complications. Studies have shown that besides cerebrovascular and cardiovascular diseases,eye diseases,renal diseases,and nervous system disease,type 2 diabetes also has the complications of hypertension,abnormal blood lipid levels,and abnormal liver function,which can bring serious damage to the body. This article reviews the association between type 2 diabetes and liver dysfunction and related features of these diseases,in order to deepen the understanding of patients with liver dysfunction and type 2 diabetes and provide a reference for clinical diagnosis and treatment.
- diabetes mellitus,type 2 /
- diabetes complications /
- non-alcoholic fatty liver disease /
- liver cirrhosis

HTML全文

参考文献(44)

[1] ZHANG B,YANG WY. Outlook for the epidemiology and prevention of diabetes in China[J]. Chin J Diabetes,2019,11(1):7-10.(in Chinese)张波，杨文英．中国糖尿病流行病学及预防展望[J]．中华糖尿病杂志，2019,11(1):7-10.

[2] American Diabetes Association. Erratum. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016; 39(Suppl. 1):s13-s22[J]. Diabetes Care,2016,39(9):1653.

[3] ZOU X,ZHOU X,ZHU Z,et al. Novel subgroups of patients with adult-onset diabetes in Chinese and US populations[J].Lancet Diabetes Endocrinol,2019,7(1):9-11.

[4] CHENG YD,YANG DH,XU BY,et al. Characterization and analysis of causes for abnormal liver functions in patients with type 2 diabetes menitus[J]. J Med Res,2017,46(10):76-80,83.(in Chinese)程艳冬，杨东辉，许碧云，等．2型糖尿病患者肝功能损害特征以及原因分析[J]．医学研究杂志，2017,46(10):76-80,83.

[5] SHIBABAW T,DESSIE G,MOLLA MD,et al. Assessment of liver marker enzymes and its association with type 2 diabetes mellitus in Northwest Ethiopia[J]. BMC Res Notes,2019,12(1):707.

[6] LEE DH,HA MH,KIM JH,et al. Gamma-glutamyltransferase and diabetes-a 4 year follow-up study[J]. Diabetologia,2003,46(3):359-364.

[7] HICKMAN IJ,RUSSELL AJ,PRINS JB,et al. Should patients with type 2 diabetes and raised liver enzymes be referred for further evaluation of liver disease?[J]. Diabetes Res Clin Pract,2008,80(1):e10-e12.

[8] NAUNYN B. Glykosurie und diabetes durch experimentelle Insulte und Krankheiten der Leber[M]//Naunyn B. Der Diabetes mellitus. Vienna,Austria:A. Holder,1898:38-49.

[9] SHERIGAR JM,CASTRO J,YIN YM,et al. Glycogenic hepatopathy:A narrative review[J]. World J Hepatol,2018,10(2):172-185.

[10] DHARMALINGAM M,YAMASANDHI PG. Nonalcoholic fatty liver disease and type 2 diabetes mellitus[J]. Indian J Endocrinol Metab,2018,22(3):421-428.

[11] HARRISON SA,BRUNT EM,GOODMAN ZD,et al. Diabetic hepatosclerosis:Diabetic microangiopathy of the liver[J].Arch Pathol Lab Med,2006,130(1):27-32.

[12] CAI XZ,LI HN,ZHANG W,et al. Clinical characteristics of patients with diabetic hepatopathy[J]. J Pract Diabetol,2014,10(1):42-43.(in Chinese)蔡祥增，李红宁，章雯，等．糖尿病性肝病的临床特点分析[J]．实用糖尿病杂志，2014,10(1):42-43.

[13] BORA K,BORAH M,CHUTIA H,et al. Presence of concurrent derangements of liver function tests in type 2 diabetes and their relationship with glycemic status:A retrospective observational study from meghalaya[J]. J Lab Physicians,2016,8(1):30-35.

[14] LU MY,LI J. Pathogenesis and diagnosis and treatment of hepatogenous diabetes[J]. J Jinzhou Med Univ,2018,39(6):92-96.(in Chinese)鲁明月，李静．肝源性糖尿病的发病机制及诊疗进展[J]．锦州医科大学学报，2018,39(6):92-96.

[15] KURIYAMA S,MIWA Y,FUKUSHIMA H,et al. Prevalence of diabetes and incidence of angiopathy in patients with chronic viral liver disease[J]. J Clin Biochem Nutr,2007,40(2):116-122.

[16] de SILVA N,BORGES MC,HINGORANI AD,et al. Liver function and risk of type 2 diabetes:Bidirectional mendelian randomization study[J]. Diabetes,2019,68(8):1681-1691.

[17] HAMED AE,ELSAHAR M,ELWAN NM,et al. Managing diabetes and liver disease association[J]. Arab J Gastroenterol,2018,19(4):166-179.

[18] XU YQ,JI Y. Liver disease and diabetes mellitus[J]. Chin J Pract Intern Med,2011,31(9):674-675.(in Chinese)徐有青，冀杨．糖尿病与肝病[J]．中国实用内科杂志，2011,31(9):674-675.

[19] YANG RX,FAN JG. Epidemiological features of non-alcoholic fatty liver diseases[J]. Infect Dis Info,2018,31(2):101-104,111.(in Chinese)杨蕊旭，范建高．非酒精性脂肪性肝病的流行特征[J]．传染病信息，2018,31(2):101-104,111.

[20] ANSTEE QM,MCPHERSON S,DAY CP. How big a problem is non-alcoholic fatty liver disease?[J]. BMJ,2011,343:d3897.

[21] MCPHERSON S,HARDY T,HENDERSON E,et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies:Implications for prognosis and clinical management[J]. J Hepatol,2015,62(5):1148-1155.

[22] RAFIQ N,BAI C,FANG Y,et al. Long-term follow-up of patients with nonalcoholic fatty liver[J]. Clin Gastroenterol Hepatol,2009,7(2):234-238.

[23] BALLESTRI S,ZONA S,TARGHER G,et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis[J]. J Gastroenterol Hepatol,2016,31(5):936-944.

[24] TARGHER G,LONARDO A,BYRNE CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus[J]. Nat Rev Endocrinol,2018,14(2):99-114.

[25] LIU XZ,XU JX. Research progress on the relationship between intestinal flora and nonalcoholic fatty liver[J]. Chin J Gerontol,2019,39(11):2815-2818.(in Chinese)刘晓贞，徐积兄．肠道菌群与非酒精性脂肪肝关系的研究进展[J]．中国老年学杂志，2019,39(11):2815-2818.

[26] VALENTI L,BUGIANESI E,PAJVANI U,et al. Nonalcoholic fatty liver disease:Cause or consequence of type 2 diabetes?[J]. Liver Int,2016,36(11):1563-1579.

[27] ABBOUD W,ABDULLA S,AL ZAABI M,et al. Young man with hepatomegaly:A case of glycogenic hepatopathy[J].Case Reports Hepatol,2018,2018:6037530.

[28] DEEMER KS,ALVAREZ GF. A rare case of persistent lactic acidosis in the ICU:Glycogenic hepatopathy and mauriac syndrome[J]. Case Rep Crit Care,2016,2016:6072909.

[29] KHOURY J,ZOHAR Y,SHEHADEH N,et al. Glycogenic hepatopathy[J]. Hepatobiliary Pancreat Dis Int,2018,17(2):113-118.

[30] KING RJ,HARRISON L,GILBEY SG,et al. Diabetic hepatosclerosis:Another diabetes microvascular complication?[J].Diabet Med,2016,33(2):e5-e7.

[31] CHEN G,BRUNT EM. Diabetic hepatosclerosis:A 10-year autopsy series[J]. Liver Int,2009,29(7):1044-1050.

[32] WANG Z,HE QH,YANG L,et al. Clinicopathologic features of hepatic diabetic microangiopathy[J]. Chin J Pathol,2012,41(10):676-680.(in Chinese)王征，何清华，杨丽，等．糖尿病肝微血管病变临床病理学观察[J]．中华病理学杂志，2012,41(10):676-680.

[33] NAZZARI E,GRILLO F,CELIENTO T,et al. Diabetic hepatosclerosis presenting with severe cholestasis[J]. Diabetes Care,2013,36(12):e206.

[34] ELKRIEF L,RAUTOU PE,SARIN S,et al. Diabetes mellitus in patients with cirrhosis:Clinical implications and management[J]. Liver Int,2016,36(7):936-948.

[35] LEE WG,WELLS CI,MCCALL JL,et al. Prevalence of diabetes in liver cirrhosis:A systematic review and meta-analysis[J]. Diabetes Metab Res Rev,2019,35(6):e3157.

[36] GARCA-COMPEN D,GONZLEZ-GONZLEZ JA,LAVALLE-GONZLEZ FJ,et al. Hepatogenous diabetes:Is it a neglected condition in chronic liver disease?[J]. World J Gastroenterol,2016,22(10):2869-2874.

[37] KUMAR R. Hepatogenous diabetes:An underestimated problem of liver cirrhosis[J]. Indian J Endocrinol Metab,2018,22(4):552-559.

[38] KAWAGUCHI T,TANIGUCHI E,ITOU M,et al. Insulin resistance and chronic liver disease[J]. World J Hepatol,2011,3(5):99-107.

[39] MARUYAMA H,KOBAYASHI K,KIYONO S,et al. Interrelationship between insulin resistance and portal haemodynamic abnormality in cirrhosis[J]. Int J Med Sci,2017,14(3):240-245.

[40] HAMED AE,ELSAHAR M,ELWAN NM,et al. Managing diabetes and liver disease association[J]. Arab J Gastroenterol,2018,19(4):166-179.

[41] MILMAN N,PEDERSEN P，STEIG T,et al. Clinically overt hereditary hemochromatosis in Denmark 1948-1985:Epidemiology,factors of significance for long-term survival,and causes of death in 179 patients[J]. Ann Hematol,2001,80(12):737-744.

[42] TRAUSSNIGG S,KIENBACHER C,HALILBASIC E,et al. Challenges and management of liver cirrhosis:Practical issues in the therapy of patients with cirrhosis due to NAFLD and NASH[J].Dig Dis,2015,33(4):598-607.

[43] TIAN J,MENG QH,LIANG QY,et al. Research progress on the relationship between metabolic diseases and therapeutic drugs and liver cancer[J]. Chin J Clin Pharmacol Ther,2019,24(1):103-110.(in Chinese)田婧，蒙秋华，梁秋云，等．代谢性疾病及治疗药物与肝癌的相关性研究进展[J]．中国临床药理学与治疗学，2019,24(1):103-110.

[44] SHI F,LEI YP. Effect of statins on hepatocellular carcinoma in patients with type 2 diabetes[J]. J Clin Hepatol,2019,35(1):161-163.(in Chinese)施凤，雷宇鹏．他汀类药物对2型糖尿病患者发生肝细胞癌风险的影响[J]．临床肝胆病杂志，2019,35(1):161-163.

施引文献

资源附件(0)

访问统计